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Abstract The objective was to assess the effectiveness of
supportive underwear (Pro-Portare®) in women with pelvic
organ prolapse. Symptomatic women with all stages of
prolapse participated in the study and were followed up for
4 weeks. The effectiveness of Pro-Portare® was measured
by three validated disease-specific quality-of-life question-
naires, a daily diary and a questionnaire on comfort and
effectiveness. Thirteen women were included in the study.
No improvement on quality of life was found with the use
of Pro-Portare®. None of the women regarded Pro-Portare®
as very effective, whereas five women regarded the device
as (reasonably) effective. The women’s major concern was
on the size, shape and hard consistency of the inlet. Two
women experienced worsening of their prolapse. Pro-
Portare® was not effective in the alleviation of prolapse
symptoms and was no final solution in any of the women.
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Abbreviations
POP pelvic organ prolapse
POPQ pelvic organ prolapsed quantification
UDI Urogenital Distress Inventory
DDI Defecatory Distress Inventory
IIQ Incontinence Impact Questionnaire
p p value for differences within the group using
Wilcoxon signed-rank test for two related samples
Introduction
Pelvic organ prolapse is a major health care problem.
Eleven percent of women will undergo surgical pelvic
reconstructive therapy during a lifetime, and surgery is
considered the most effective therapy [1]. However,
recurrence rates are high, and surgery is not feasible in all
patients. Currently, the only other viable option is pessary
treatment. Pessaries are considered safe and easy to use.
Prospective observational studies show success rates be-
tween 60% and 80% [2], which decline with increasing
parity and the duration of pessary use [3, 4]. In some
women, however, pessary use is not feasible due to pain,
erosion or repeated loss of the pessary [3, 4]. Recently, a
medical device has been developed for use in these patients
with pelvic organ prolapse. Pro-Portare® provides support
to the pelvic floor and prevents the descent of the pelvic
organs outside the vagina as well as symptomatic descent of
the pelvic floor itself (descending perineum).
At present, the effectiveness of any kind of supportive
underwear in women with symptoms of pelvic organ
prolapse is unknown, and there are no scientific data
available up till now. Our hypothesis is that Pro-Portare®
has a positive effect on the quality of life in women with
pelvic organ prolapse.
Int Urogynecol J (2008) 19:1519–1522
DOI 10.1007/s00192-008-0676-x
DO00676; No of Pages
K. Lammers :M. E. Vierhout :M. I. J. Withagen :
K. B. Kluivers (*)
Department of Obstetrics and Gynaecology,
Radboud University Nijmegen Medical Centre,
791, Postbus 9101,
6500 HB Nijmegen, The Netherlands
e-mail: K.Kluivers@obgyn.umcn.nl
Materials and methods
This prospective observational study was conducted in a
tertiary referral urogynaecological clinic at the Radboud
University Nijmegen Medical Centre, The Netherlands,
from January till December 2006. The local ethics
committee has approved the study, and all participants
gave their informed consent.
All patients with pelvic organ prolapse quantification
(POPQ) stage, who were either awaiting surgical correction
or were not eligible for surgical or pessary therapy, were
asked to participate in the study. The exclusion criterion
was the inability to speak the Dutch language. The patient’s
selection was not consecutive but depended mainly on the
availability of the researchers.
The supportive underwear consisted of tricot-knitted
knickers with Velcro in the waist and a silicone inlet that
supports the pelvic floor and the prolapse (Figs. 1 and 2).
Verbal and written information on the use of Pro-
Portare® was provided. The women were given two sets
of Pro-Portare® on loan for 4 weeks, and they were asked
to wear Pro-Portare® for these 4 weeks. The questionnaires
Urogenital Distress Inventory (UDI), Incontinence Impact
Questionnaire (IIQ) and Defecatory Distress Inventory
(DDI) were completed at baseline and at the end of the
study period [5]. The UDI consists of 11 items and five
subscales on bothersome urinary complaints. The IIQ
consists of 13 items and measures the impact of urinary
incontinence on quality of life in five subscales. The DDI
measures bothersome defecatory complaints and consists of
ten items and four subscales. The score on each subscale of
these questionnaires ranges from 0–100, where 0 indicates
the best quality of life and 100 indicates the poorest quality
of life.
The women kept a daily diary. The diary was introduced
with a statement that the aim was to report on their physical
activities and their findings in relation to the supportive
underwear. The number of days the women had worn the
supportive underwear were recorded in the diary.
Furthermore, a self-developed questionnaire on the
patients’ perception of the comfort and the effectiveness
of Pro-Portare® was completed at the end of the study
period. The following questions were asked:
1. What is your overall impression on the comfort of
Pro-Portare®?
2. What is your opinion on the effectiveness of
Pro-Portare®?
The possible answers to the first question were good,
neutral and poor. The possible answers to the second
question were very effective, effective, reasonably effec-
tive, not effective and worsening of symptoms. In case the
women noted worsening of symptoms, clinical examination
(POPQ) was repeated at the end of the study period.
The women completed the UDI, IIQ and DDI at
baseline, which was prior to the use of Pro-Portare®. The
second measurement was ideally after 4 weeks. In case a
woman stopped using Pro-Portare® before the end of the
study period of 4 weeks, however, the UDI, IIQ and DDI as
well as the questionnaire on the comfort and effectiveness
were completed at that timepoint.
Differences within the group (at baseline and the end of
the study period) were tested for statistical significance
using the Wilcoxon signed-rank test for two related
samples. Software package Statistical Package for the
Social Sciences 13.0 (SPSS, Chicago, IL, USA) was usedFig. 1 Pro-Portare®: the tricot-knitted knickers with Velcro in the waist
Fig. 2 Pro-Portare®: the silicone inlet
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for statistical analysis. p values <0.05 were considered
statistically significant.
Results
Thirteen women were included in this study, with POPQ
stages 1–4 prolapse [three women (23%), stage 1; four
women (31%), stage 2; four women (31%), stage 3; and
two women (15%), stage 4). Their median age was 67 years
(range, 49–85 years), and the median body mass index was
25.1 kg/m2 (range, 22.1–36.3 kg/m2). All women had
symptoms of pelvic organ prolapse, of which four women
(31%) had previously undergone prolapse surgery. Four
women (31%) were on the surgical waiting list for prolapse
surgery during the study period, whereas another six
women (46%) underwent surgical prolapse correction
within 6 months after completion of the study. The
remaining three women (23%) were not eligible for surgery.
Seven women (56%) reported symptoms of urinary
incontinence more than once a week. Three women (23%)
had pelvic floor physiotherapy in the period immediately
prior to the study but not during the study period. Three out
of 12 post-menopausal women (25%) were on local
estrogen therapy or hormonal replacement therapy.
The median number of days until the end of the study
period was 11 days (range, 1–28 days). Only two women
have worn the Pro-Portare® during the entire 4-week period.
Twelve women (92%) completed the questionnaires
UDI, IIQ and DDI at both timepoints. The results were as
shown in Table 1. The differences between the baseline
measurement and measurement at the end of the study
period were not statistically significant.
Nine women (69%) completed the daily diary and the
questionnaire on their findings with respect to comfort and
effectiveness. Three women (33%) considered the comfort
of Pro-Portare® as good and two women (22%) as poor.
The other four women (44%) answered neutral. Regarding
the effectiveness of Pro-Portare®, none of the women
regarded the device as very effective, whereas five women
considered the device either effective (22%) or reasonably
effective (33%). Two women (22%) stated that the
supportive underwear was not effective, and another two
women (22%) experienced worsening of the prolapse
symptoms. In these two women, the worsening was also
seen on clinical examination (POPQ point Ba from +1 to
+3 cm and from +1 to +2 cm at baseline and after 4 weeks,
respectively).
The women’s perceptions as stated in the diary were as
follows: The silicone inlet was experienced as too hard
(five women, 56%), too large (three women, 33%) and too
stiff (one woman, 11%). Consequently, the underwear was
getting visible under normal clothes and caused some
problems with skin irritation on the inside of the legs. The
Pro-Portare® was considered comfortable during walking,
housekeeping and shopping, whereas sitting on a hard
underground or riding a bicycle was generally considered
uncomfortable.
One woman continued to wear Pro-Portare® for 6 months
after the study period and subsequently underwent pro-
Table 1 Subscales of the Urogenital Distress Inventory, Defecatory Distress Inventory and Incontinence Impact Questionnaire at baseline and at
the end of the individual study period of Pro-Portare®
Baseline (n=12) End of study period (n=12) p value
UDI overactive bladder 33 (0–100) 67 (0–100) 0.25
UDI urinary incontinence 25 (0–100) 33 (0–100) 0.41
UDI obstructive micturition 33 (0–100) 67 (0–83) 0.26
UDI discomfort/pain 33 (0–100) 17 (0–83) 1.00
UDI genital prolapse 33 (0–100) 67 (17–100) 0.59
DDI constipation 0 (0–83) 8 (0–67) 0.28
DDI obstructive defecation 8 (0–75) 0 (0–83) 0.21
DDI pain 0 (0–100) 0 (0–100) 1.00
DDI incontinence 0 (0–171) 0 (0–17) 1.00
IIQ physical functioning 25 (0–100) 33 (0–67) 0.06
IIQ mobility 39 (0–100) 50 (0–78) 0.11
IIQ social functioning 11 (0–67) 22 (0–78) 0.26
IIQ embarrassment 0 (0–50) 0 (0–67) 0.56
IIQ emotional health 22 (0–56) 17 (0–67) 0.22
Data presented as median (range). The score on each subscale ranges from 0–100, where 0 indicates the best quality of life and 100 indicates the
poorest quality of life. Note that one woman was lost to follow-up.
UDI Urogenital Distress Inventory, DDI Defecatory Distress Inventory, IIQ Incontinence Impact Questionnaire, p p value for differences within
the group using Wilcoxon signed-rank test for two related samples
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lapse surgery due to progressive signs and symptoms of
prolapse.
Discussion
In this pilot study, we have evaluated the effectiveness of
supportive underwear (Pro-Portare®) in 13 women with
pelvic organ prolapse. There was no improvement in
quality of life with the use of Pro-Portare®, and none of
the women has used Pro-Portare® beyond the time period
of 6 months. To our knowledge, this is the first report on
the effectiveness of supportive underwear in women with
pelvic organ prolapse. As compared with data on surgical
therapy and pessaries, Pro-Portare® seems to be a less
effective treatment option [1, 2].
In this study, half of the women had a POPQ stage 1 or 2
prolapse. Especially, a stage 1 prolapse is generally not
regarded as a pathological finding. The POPQ and other
staging systems, however, disregard the descent of the
perineum or pelvic floor. Due to the nature of our clinic,
which is a tertiary referral centre, women with symptoms
but no signs of prolapse are probably slightly overrepre-
sented. We were not able, however, to demonstrate a
difference in effectiveness of Pro-Portare® in these women.
Two women (15%) have noted that their prolapse had
worsened during the study period. This worsening was seen
on clinical examination as well. However, not all women in
the study underwent prolapse staging at the end of the study
period. It is not known whether this worsening is a side
effect of the Pro-Portare® or just represents the natural
course of prolapse. This needs to be investigated in future
studies on supportive underwear in women with prolapse.
Pro-Portare® is not yet registered as a medical device and
is thus not covered by the Dutch health insurance companies.
Pro-Portare®, as a set of two pieces of underwear and one
silicone inlet, costs approximately 300 € (US $200). Only
one size of Pro-Portare® is available until now. The hard
consistency and the size of the inlet have caused discomfort
to the women in the study. Whether a thinner version of the
silicone inlet with more souplesse would be more effective
needs to be awaited. Further development of the device in
various sizes is pending.
An obvious limitation of this study is its small sample
size. Moreover, the results from this small pilot study are
rather negative. In all likelihood, however, these results
would not change if more women would have been
included. To our opinion, it is of utmost importance that
negative results are also published and are appreciated by
gynaecologists in the field. To what extent the lack of
effectiveness is due to the lack of comfort of the device as
used in the study is, however, not known until now.
In conclusion, Pro-Portare® did not change the quality of
life in the women included in this study. Furthermore, Pro-
Portare® was no final solution in any of these women.
Although there are only few treatment options for women
with pelvic organ prolapse, at this stage, broad implemen-
tation of supportive underwear is not very likely.
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